Evidence map›Paper›PMID 40824508›Full record

ArticleDiscover oncology2025

Chemotherapy response in primary peritoneal small cell carcinoma.

Kholoud Alqasem, Sakhr Alshwayyat, Salsabeel Aljawabrah, Sundus Yahya Nser, Ala'aldin Eqleem, Mohammad Abu Shattal, Maisoon Hajir, Mohammed Al-Mahdi Al-Kurdi

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kholoud AlqasemDepartment of Internal Medicine, King Hussein Cancer Center, Queen Rania Al Abdullah Street, P.O. Box: 1269, Amman, 11941, Jordan.
Sakhr AlshwayyatResearch Center, King Hussein Cancer Center, Amman, Jordan.ORCID http://orcid.org/0000-0002-2295-1945
Salsabeel AljawabrahSchool of Medicine, The University of Jordan, Amman, Jordan.
Sundus Yahya NserSchool of Medicine, Faculty of Medicine, Hashemite University, Zarqa, Jordan.
Ala'aldin EqleemSchool of Medicine, The University of Jordan, Amman, Jordan.
Mohammad Abu ShattalDepartment of Radiology, King Hussein Cancer Center, Amman, Jordan.
Maisoon HajirDepartment of Internal Medicine, King Hussein Cancer Center, Queen Rania Al Abdullah Street, P.O. Box: 1269, Amman, 11941, Jordan.
Mohammed Al-Mahdi Al-KurdiFaculty of Medicine, University of Aleppo, Aleppo, Syria. mohammedmahdikurdi@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmall cell carcinoma (SCC) is a neuroendocrine tumor that usually originates in the lungs but can also arise from extrapulmonary sites. Extrapulmonary small cell carcinomas (EPSCCs) are aggressive and rare, with limited data guiding their management. This case report contributes to the literature by presenting the diagnosis and treatment of primary peritoneal SCC. CASE PRESENTATION: This case describes a 69-year-old man who presented with abdominal distension and pain, raising concerns for metastasis. He had a history of prostate cancer treated with radical prostatectomy and pelvic lymph node dissection. Biopsy and imaging revealed metastatic SCC involving the peritoneum and omentum. A diagnosis of primary peritoneal SCC or SCC of unknown primary origin was made due to the absence of a detectable primary tumor in typical sites. The patient underwent three separate courses of carboplatin/etoposide chemotherapy (6 cycles each), with each course resulting in significant disease regression and symptom relief. Recurrence was managed effectively with repeated chemotherapy cycles, but long-term follow-up showed the need for continued treatment to maintain disease control and quality of life.

conclusionThis case underscores the importance of a multidisciplinary approach and patient-centered care in managing rare cancers like primary peritoneal SCC. Further research is essential to clarify its molecular characteristics and improve therapeutic options.

Indexed as

ChemotherapyExtrapulmonary small cell carcinomasNeuroendocrine tumorsPeritonealSmall cell carcinoma

Identifiers

PMID40824508
PMCPMC12360997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.